جست‌وجوی استاد و پژوهشگر

• Stem Cell Biology
• Cell Biology
• Developmental Biology
• +۵ مورد دیگر

Anika Böttcher serves as Group Leader of the Intestinal Stem Cell Research group at the Institute of Diabetes and Regeneration Research (IDR), Helmholtz Munich, Germany, a position she has held since 2016. Her work bridges cell biology, developmental mechanisms, and metabolic disease research with a focus on therapeutic applications for diabetes and obesity. Her academic foundation includes a Diploma in Biology from the University of Jena (Germany) and University of Lund (Sweden), followed by a PhD at the Max Planck Institute of Biochemistry under Reinhard Fässler investigating integrin signaling in kidney development. She completed postdoctoral training at Helmholtz Munich with Heiko Lickert, studying Wnt/Planar Cell Polarity signaling in gut development. Böttcher's research centers on deciphering how biomechanical signals govern intestinal stem cell fate decisions, particularly in enteroendocrine lineage formation. Her team employs single-cell genomics, mouse models of diet-induced obesity, and molecular techniques to uncover mechanisms linking gut dysfunction to metabolic disorders. Key interests include stem cell plasticity, cellular polarity, and the role of specific enteroendocrine cell subsets in obesity pathogenesis. Analysis of her publication record reveals consistent focus on intestinal stem cell regulation in metabolic disease contexts, with increasing emphasis on single-cell resolution of cellular heterogeneity and diet-induced molecular reprogramming since 2017. Her work demonstrates how obesogenic diets alter stem cell identity through PPAR signaling and insulin pathways, directly linking gut maladaptation to systemic metabolic syndrome. Her scientific recognition includes: Transregional Collaborative Research Centre 127 (2020-2024) German Center for Diabetes Research (DZD) funding (2018-2019) Max Planck Junior Research Award (2010) Rupert Timpl Award from the International Society for Matrix Biology (2010) As group leader, Böttcher directs research supported by major grants from the DFG and DZD, with collaborative projects spanning diabetes mechanism elucidation to therapeutic development. Her team maintains active partnerships with the German Center for Diabetes Research and participates in transregional consortia focused on regenerative approaches. The Intestinal Stem Cell Research group operates within Helmholtz Munich's IDR facility, utilizing advanced genomic, imaging, and mouse phenotyping platforms. Their work connects fundamental stem cell biology with translational applications, particularly in developing gut-based interventions for metabolic disorders through manipulation of enteroendocrine cell differentiation.

Maria Elena Torres-Padillaمشاهده پروفایل

استاد

• Epigenetics
• Stem Cell Biology
• Heterochromatin formation
• +۵ مورد دیگر

Prof. Maria Elena Torres-Padilla is Director of the Institute of Epigenetics and Stem Cells at Helmholtz Zentrum München and Professor (W3) Chair of Stem Cell Biology at the Faculty of Biology, Ludwig-Maximilians-University Munich. She also serves as Vice Chair of the CRC 1064 and holds an Honorary Professorship at the University of Aarhus Denmark. Her leadership extends to coordinating the EpiGene2Sys Network and serving on the Steering Board of Single Cell Omics Germany. Her research focuses on epigenetic mechanisms during early mammalian development, particularly: Heterochromatin formation and silencing in mouse embryos The role of pericentromeric RNA in chromatin organization Phase separation potential of heterochromatin proteins Nuclear reprogramming and cellular plasticity Genome-lamina interactions during embryonic development Prof. Torres-Padilla's recent publications demonstrate a strong focus on chromatin dynamics during early embryonic development, with particular emphasis on heterochromatin establishment and the potential role of phase separation mechanisms. Her work combines advanced genomic, transcriptomic, and imaging approaches to address fundamental questions in epigenetics. Her scientific achievements have been recognized with numerous awards: Elected EMBO Member (2015) Female Award of the German Stem Cell Network (2018) ERC Starting Grant awardee (2011) EMBO Young Investigator (2011) Selected as Extraordinary Young Scientist by the World Economic Forum (2015) Prof. Torres-Padilla maintains an active research program with significant funding support. She leads Project A24 within CRC 1064 investigating heterochromatin formation in mouse embryos. Her laboratory at the Institute of Epigenetics and Stem Cells provides training for PhD students and postdoctoral researchers, with opportunities to work on cutting-edge epigenetics research using state-of-the-art technologies. She directs the Institute of Epigenetics and Stem Cells (IES), a research group focused on understanding the epigenetic mechanisms that govern stem cell identity and early embryonic development. The institute employs advanced genomic, imaging, and biochemical approaches to investigate chromatin organization and nuclear reprogramming.

• Synthetic Biology
• Gene Editing
• Genomics
• +۶ مورد دیگر

Farren Isaacs is a Professor of Molecular, Cellular and Developmental Biology at Yale School of Medicine with extensive affiliations across Yale University. His primary appointments include the Department of Molecular, Cellular and Developmental Biology, Microbiology, and the Yale Cancer Center. He also participates in the Center for RNA Science and Medicine, Genomics, Genetics and Epigenetics Program, Molecular Cell Biology, Genetics and Development, Yale Combined Program in the Biological and Biomedical Sciences (BBS), and Yale Ventures. Dr. Isaacs received his BS in Bioengineering from the University of Pennsylvania, followed by MS and PhD degrees in Biomedical Engineering and Bioinformatics from Boston University. He completed postdoctoral training at Harvard Medical School before establishing his independent research program at Yale. His research focuses on developing and applying genome engineering technologies to understand and reprogram biological systems. His lab has pioneered approaches like MAGE (Multiplex Automated Genome Engineering) and has made significant contributions to genome recoding, CRISPR-based editing, and synthetic genetic circuit design. Recent work includes engineering genomically recoded organisms with simplified genetic codes and developing precision multiplexed base editing techniques with potential therapeutic applications. Dr. Isaacs' publication record demonstrates sustained innovation in synthetic biology and genome engineering, with high-impact papers spanning from foundational work in the early 2000s to multiple 2025 publications in journals like Nature, Nature Communications, and Science. His research trajectory shows a clear progression from developing basic genome engineering tools to applying these technologies to increasingly complex biological problems. Beckman Young Investigator Award (2012) Rising Young Stars of Science (2008) Dr. Isaacs maintains an active research program with multiple current grants supporting work in genome engineering and synthetic biology. His lab trains graduate students and postdoctoral fellows in cutting-edge genomic technologies while fostering interdisciplinary collaborations across Yale and with external institutions. The lab operates across two locations - at Yale's main Science Hill campus and at the West Campus facility. The Isaacs Lab focuses on developing next-generation genome engineering technologies and applying them to fundamental biological questions and potential therapeutic applications. Current research directions include expanding the genetic code, developing precision editing tools, and creating synthetic biological systems with novel properties and enhanced biocontainment features.

• Immunology
• Virology
• Vaccine Development
• +۵ مورد دیگر

Akiko Iwasaki is Sterling Professor of Immunobiology at Yale School of Medicine, with secondary appointments in Dermatology and Epidemiology of Microbial Diseases. She serves as Director of Yale's Center for Infection and Immunity and has been an HHMI Investigator since 2014. Her affiliations include joint roles with Yale Cancer Center, Center for RNA Science, and Women's Health Research at Yale. Her research focuses on: Mucosal immune defense mechanisms against viruses Long COVID pathophysiology and neuroimmune interactions Development of nasal vaccines to block viral transmission Virus-triggered autoimmunity and cancer pathogenesis Recent publications emphasize SARS-CoV-2 immunology, with trends showing strong focus on: Characterization of post-viral syndromes (Long COVID, ME/CFS) Mucosal vaccine efficacy and IgA response modulation Viral reservoir identification and therapeutic targeting Neuroimmune mechanisms in chronic disease Major scientific honors include: Keio Medical Science Prize (2025) TIME 100 Most Influential People (2024) National Academy of Sciences membership (2018) Else Kröner Fresenius Prize (2023) AAI Presidency (2023) She directs the Iwasaki Lab and Center for Infection and Immunity, coordinating multicenter studies like the Yale-Mount Sinai Long COVID initiative. As principal investigator of NIH-funded projects, she mentors graduate students and oversees translational research bridging virology and clinical immunology.

• Metabolomics
• Colorectal cancer
• Sex-specific differences in cancer
• +۷ مورد دیگر

Caroline Helen Johnson, PhD, is a Tenured Associate Professor of Epidemiology in the Department of Environmental Health Sciences at Yale School of Public Health. She holds multiple joint appointments across Yale University, including at the Yale Cancer Center, Department of Microbiology, and Program in Translational Biomedicine. Her research integrates metabolomics with epidemiology to investigate sex-specific differences in colorectal cancer and environmental exposures. Dr. Johnson's primary research focuses on sex-specific differences in colorectal cancer metabolism. In 2020, her lab published the first sex-stratified metabolomics analysis of tumor tissues from colorectal cancer patients, revealing that aberrant asparagine metabolism is a hallmark of tumors from female patients only and associates with poorer clinical outcomes. Her lab also studies early-onset colorectal cancer (under age 50), discovering distinct metabolic profiles in younger patients including downregulated dopamine metabolism and increased phospholipid metabolism. Additionally, her team investigates environmental exposures and their biological impacts using metabolomics, with particular expertise in analyzing dried blood spots to measure early-life exposures that may contribute to later-life cancer development. Dr. Johnson's recent publications (2024-2025) demonstrate a strong focus on sex-specific cancer biology, with multiple papers examining asparagine metabolism in colorectal cancer, sex differences in tumor growth, and the development of comprehensive databases documenting sex-based differences in oncologic diseases. Her work spans multiple disciplines including cancer metabolism, microbiome research, environmental toxicology, and clinical oncology. YSPH Impact Prize (2025) YSPH Team Science Research Award (2024) International Metabolomics Society Career Medal (2023) Metabolomics Association of North America Women in Science (Womix) mentorship award (2023) K12 Calabresi Immuno-Oncology Training Program Award (2021) Dr. Johnson serves as Associate Editor for both Metabolomics and Toxicological Sciences journals and has advised numerous students, including PhD candidate Xinyi Shen. Her lab has developed specialized protocols for metabolite normalization in various clinical matrices and maintains active collaborations across Yale's medical and public health schools. Current research directions include validating findings on early-onset colorectal cancer metabolism, understanding the mechanisms behind sex-specific asparagine metabolism in cancer, and expanding the application of metabolomics to assess environmental exposures and their biological impacts.

• Apoptosis
• Cell Death
• BCL-2 Proteins
• +۹ مورد دیگر

Samuel G. Katz, MD, PhD is an Associate Professor of Pathology at Yale University School of Medicine with primary appointments in Pathology and multiple secondary affiliations including Genomics, Genetics and Epigenetics, Hematopathology, Molecular Medicine, Pharmacology and Physiology, and the Yale Cancer Center. His research bridges fundamental cell death mechanisms with translational immunotherapy approaches. Dr. Katz earned his combined B.S./M.S. from Yale University in 1995, followed by dual M.D./Ph.D. training through the Health Sciences & Technology program at MIT and Harvard. His PhD thesis with Stuart H. Orkin focused on transcriptional regulation of hematopoiesis. He completed pathology residency and hematopathology fellowship at Brigham and Women's Hospital, followed by postdoctoral studies on apoptosis with Loren D. Walensky at Dana Farber Cancer Institute. His research focuses on BCL-2 family proteins, particularly the poorly understood BOK protein, which resides in one of the 20 most frequently deleted genomic regions in human cancers. The lab investigates how BCL-2 proteins regulate cell viability and integrate multiple cellular functions beyond apoptosis. Using conditional mouse knockouts, biochemistry, and genetic screening, the lab aims to unravel complex cellular signaling pathways to develop therapeutic strategies against cancer. The Katz Lab has published consistently in high-impact journals with recent work spanning from fundamental BCL-2 protein mechanisms to CAR-T cell engineering. The lab's research shows a clear trajectory from basic molecular mechanisms to translational immunotherapy applications, particularly in lymphoma and leukemia. Mantle Cell Lymphoma Consortium Member (2011) Career Development Award, Mentored (K08) from NIH (2010) Post-Doctoral Fellow Career Development Award from Leukemia and Lymphoma Society (2008) Yamaguchi Award in Hematology Research (1999) Pre-Doctoral Fellow Award from Howard Hughes Medical Institute (1998) Dr. Katz leads a vibrant research group that includes graduate students, postdoctoral associates, and research scientists. His lab collaborates extensively with the Yale New Haven Hospital's Advanced Cell Therapy core and clinical oncologists. The lab was recently awarded an NIH grant to study the role of BOK protein in the cell death pathway, demonstrating continued research excellence and funding success. Dr. Katz also maintains active clinical work as a hematopathologist, diagnosing blood cancers and collaborating with clinicians on patient care. The Katz Lab maintains strong connections with the Yale Cancer Center and Yale Center for Immuno-Oncology, positioning it at the forefront of cancer research and immunotherapy development. The lab's work on reprogramming immune cells using multifactor mRNA approaches represents a cutting-edge direction in cancer treatment.

• Prostate Cancer
• Cancer Therapy Resistance
• Molecular Mechanisms
• +۷ مورد دیگر

Ping Mu is an Associate Professor with tenure in both the Department of Urology and Department of Pathology at Yale School of Medicine and a member of the Yale Cancer Center. His academic journey began with a BS in Biotechnology from Peking University (2007), followed by a PhD in Biomedical Sciences from Weill Medical College of Cornell University (2013), and postdoctoral training under Dr. Charles L. Sawyers at Memorial Sloan Kettering Cancer Center. In mid-2018, he established his independent laboratory at UT Southwestern as an assistant professor, where his research excellence led to rapid promotion to tenured associate professor before moving to Yale. Dr. Mu's research focuses on uncovering the molecular mechanisms driving resistance to targeted and immune therapies in prostate and other cancers. His lab pursues three exciting research directions: 1) Mechanisms of Therapy Resistance and Tumor Evolution, particularly lineage plasticity, epigenetic rewiring, and mutagenesis; 2) Tumor Microenvironment, Immune Modulation, and Spatial Heterogeneity; and 3) Translational Platforms: AI-Driven Precision Medicine and Patient-Derived Organoids. His work employs state-of-the-art techniques including 3D-cultured organoids, single-cell sequencing, and spatial transcriptomics. Dr. Mu's recent publications show a strong focus on lineage plasticity, epigenetic regulation, and therapy resistance mechanisms in prostate cancer. His high-impact work has been featured in top-tier journals including Science (2017), Cancer Cell (2020, 2023), Cancer Discovery (2024), Nature Cancer (2022), and Nature Genetics (2015), demonstrating a consistent trajectory of significant contributions to the field of cancer research. Selected Scientific Awards: NIH R37 MERIT Award (2021) NIH R01 Research Award (2024) AACR NextGen Stars Award (2020) Prostate Cancer Foundation Young Investigator Award Welch Foundation Research Award Dr. Mu maintains an active research program with multiple NIH and DoD-funded projects. His lab has pioneered important discoveries regarding lineage plasticity mechanisms and novel therapeutic approaches to overcome therapy resistance. The Mu Lab actively collaborates with other researchers at Yale Cancer Center and beyond, contributing to the vibrant research ecosystem at Yale. The lab is particularly known for its work with 3D-cultured organoids and spatial transcriptomics to model therapy resistance in prostate cancer.

• Cancer Genetics
• Cancer Epigenetics
• Immunobiology
• +۵ مورد دیگر

Vish Muthusamy is a Research Scientist at Yale School of Medicine with appointments in the Department of Medical Oncology and Hematology and the Developmental Therapeutics Program. He serves as the Director of the Center for Precision Cancer Modeling at Yale Cancer Center, where he focuses on advancing candidate therapeutic agents toward clinical application. Dr. Muthusamy is a cancer biologist with expertise spanning multiple disciplines: Cancer genetics and epigenetics Immunobiology and immunotherapy Pharmacological development of anti-cancer drugs Preclinical modeling and testing His research program focuses on understanding genetic alterations that drive cancer formation and progression, developing in vivo tumor models, and translating these findings into therapeutic approaches. Dr. Muthusamy frequently collaborates with medicinal chemists and has worked with both large and small pharmaceutical companies to develop therapeutic agents targeting cancer, infectious pathogens, and immune disorders. As Director of the Center for Precision Cancer Modeling, he plays a key role in Yale's translational research ecosystem, helping investigators bridge the gap between laboratory discoveries and clinical applications. Dr. Muthusamy's publication record demonstrates a strong trajectory from basic cancer biology to translational drug development. His recent work (2023-2025) focuses on overcoming checkpoint inhibitor resistance through novel immunotherapies, including IL-12 mRNA therapy and CD40 agonists. Earlier work (2016-2022) includes research on targeted therapies for specific cancer types like FGFR3-driven bladder cancer, metabolic isozyme targets in cancer, and innovative approaches to protein degradation and immune recruitment. Dr. Muthusamy maintains active collaborations across Yale and with external partners. His frequent co-authors include Katerina Politi, Marcus Bosenberg, Akiko Iwasaki, Anna Marie Pyle, and Daniel P. Petrylak, indicating strong connections across cancer biology, immunology, and clinical oncology disciplines. As Director of the Center for Precision Cancer Modeling, Dr. Muthusamy leads a research team focused on preclinical development of cancer therapeutics. The center provides expertise in developing and validating tumor models that better predict clinical response, helping Yale researchers advance their discoveries toward clinical trials and eventual patient care.

Roel Verhaakمشاهده پروفایل

استاد

• Brain Tumor Research
• Glioma Evolution
• Extrachromosomal DNA Amplification
• +۵ مورد دیگر

Roel Verhaak, PhD, is a Professor in the Department of Neurosurgery at the Yale School of Medicine, holding the prestigious Harvey and Kate Cushing Professorship. He maintains extensive affiliations across Yale's research ecosystem, including the Genomics, Genetics, and Epigenetics Program, Human Genome Sciences, Molecular Medicine, Pharmacology, and Physiology, the Neurosurgery Program in Translational Biomedicine, and the Yale Cancer Center. Dr. Verhaak earned his PhD from Erasmus University Medical Center in Rotterdam, followed by postdoctoral training at the Broad Institute/Dana-Farber Cancer Institute. He established his independent research program at MD Anderson Cancer Center in 2010, was affiliated with the Jackson Laboratory for Genomic Medicine from 2016, and joined Yale School of Medicine in 2023. His research focuses on brain tumors and extrachromosomal DNA amplification in cancer. The Verhaak Lab studies tumor evolution and therapy resistance mechanisms in gliomas using high-throughput sequencing, computational analysis, and functional studies. He leads the Glioma Longitudinal Analysis Consortium (GLASS) and made the groundbreaking discovery that extrachromosomal DNA amplifications are critical cancer drivers. Dr. Verhaak's publication record shows a consistent focus on advancing our understanding of glioma biology and cancer genomics, with recent work (2023-2025) emphasizing extrachromosomal DNA mechanisms, glioma evolution, and novel therapeutic approaches. His research has shifted from initial molecular classification work to deeper mechanistic understanding of tumor evolution and resistance. AAAS Martin and Rose Wachtel Cancer Research Award (2016) Adult Basic Science Award from the Society for Neuro-Oncology (2014) Peter Steck Memorial Award from the Pediatric Brain Tumor Foundation (2012) Wilson S. Stone Memorial Award from MD Anderson Cancer Center (2011) Dr. Verhaak actively mentors researchers and collaborates extensively across institutions. He co-founded Boundless Bio to translate his discoveries about extrachromosomal DNA into therapeutic approaches. His lab participates in major consortia including the GBM Cellular Analysis of Resistance and Evolution (CARE) consortium, which has refined our understanding of glioblastoma's cellular architecture through single-cell transcriptomics. The Verhaak Lab maintains a strong research presence with multiple active projects focused on understanding how extrachromosomal DNA drives cancer progression and developing strategies to target this mechanism therapeutically.